RxSight, Inc. — Third Quarter 2026 Earnings Summary

RxSight, Inc. reported a net loss of $16.2 million for the third quarter of 2026, with total revenue declining 19% year-over-year to $24.6 million. The company's cash, cash equivalents, and short-term investments totaled $254.7 million as of September 30, 2026, including a $60 million payment received from its collaboration with Alcon. Gross margin for the quarter decreased to 73.6% from 79.9% in the prior year period, primarily due to increased inventory reserves and higher costs. Strategic initiatives included the appointment of new commercial leadership, a significant expansion of the sales force, and the completion of an organizational restructuring to align resources with priorities.